Skip to content
ContentLora

    Tip: press / anywhere to search.

    technology

    CAR-T cell therapy

    Also known as CAR T-cell therapy, chimeric antigen receptor T-cell therapy, CAR-T

    CAR-T cell therapy re-engineers a patient's own T cells to recognise cancer and infuses them back.[1] Approved in the US since 2017 for blood cancers, it reached its first solid-tumour approval in China in June 2026.[2][3]

    Editor reviewedStrict sourcingUpdated Cancer immunotherapyHealth and medicineLife sciences
    Key facts

    CAR-T cell therapy takes a patient’s T cells, engineers them to carry a chimeric antigen receptor (CAR) that recognises a cancer target, expands them and infuses them back as a single dose.[1] The basics are explained step by step in the explainer How CAR-T cell therapy works; this page covers the approved products, regulation and the frontier. Before the infusion, patients may receive chemotherapy to reduce their other immune cells so that the transferred T cells work better.[4]

    Approvals

    The FDA approved the first CAR-T therapy, tisagenlecleucel (Kymriah), on 30 August 2017 for children and young adults with B-cell acute lymphoblastic leukaemia; 83% achieved remission within three months.[2] By 2024, six approved BCMA- or CD19-directed autologous products were on the US market.[5] More followed, including obecabtagene autoleucel for adult B-cell ALL in November 2024 and a new indication for lisocabtagene maraleucel in marginal zone lymphoma in December 2025, where 95.5% of 66 patients responded.[6][7]

    Safety and regulation

    Cytokine release syndrome and neurotoxicity (ICANS) are the main acute risks.[8] In April 2024 the FDA added a boxed warning to six CAR-T products for T-cell malignancies, including CAR-positive tumours, and said patients should be monitored life-long.[5] On 26 June 2025 the agency moved the other way on logistics, announcing that the REMS programmes for approved BCMA- and CD19-directed autologous CAR-T products had been eliminated because they were no longer needed to ensure benefits outweigh risks.[9] As a result, the recommended stay near a treatment centre fell from four weeks to two and the driving restriction from eight weeks to two.[10] A peer-reviewed analysis argued the change could widen access beyond academic centres.[10]

    Solid tumours

    NCI identifies three barriers in solid tumours: scarce target antigens, an immunosuppressive microenvironment and tumour heterogeneity.[11] In a randomised phase 2 trial in claudin-18.2-positive gastric cancer, satri-cel extended median progression-free survival from 1.77 to 3.25 months.[12] China’s NMPA approved it on 22 June 2026 for patients whose disease had progressed after at least two prior lines of therapy, described as the first CAR-T approval for a solid tumour.[13][3] In the US, the first engineered T-cell therapy for a solid tumour was not a CAR but an engineered T-cell receptor product, Tecelra, approved in August 2024 for synovial sarcoma.[14] Toxicity was substantial: grade 3 or higher adverse events occurred in 99% of satri-cel patients.[15]

    What comes next

    Two approaches aim to remove the weeks-long, patient-specific manufacturing step. Allogeneic products use healthy donors’ T cells.[16] In vivo CAR-T uses a vector to generate CAR-T cells inside the patient, with early myeloma data published in 2026.[17][18] Researchers describe ex vivo manufacturing as lengthy and costly, limiting access.[19] In mice, a 2026 study used crispr-cas9 to insert the CAR gene at a chosen site in T cells inside the body.[20] CAR-T also competes with bispecific T-cell engagers, which hit some of the same targets, such as BCMA in myeloma.[21]

    Questions readers ask

    What cancers is CAR-T approved for?

    In the US, approved autologous products target CD19 or BCMA and treat blood cancers, with indications including B-cell acute lymphoblastic leukaemia and, since December 2025, marginal zone lymphoma. In China, satri-cel was approved in June 2026 for claudin-18.2-positive gastric cancer.[5][7][3]

    Why did the FDA add a boxed warning to CAR-T?

    In April 2024 the FDA required a boxed warning for the risk of T-cell malignancies after BCMA- or CD19-directed CAR-T, and said patients should be monitored life-long.[5]

    What changed when the FDA removed the CAR-T REMS?

    The recommended stay near a treatment centre fell from four weeks to two, and the driving restriction from eight weeks to two.[10][9]

    Is CAR-T the only engineered T-cell therapy approved?

    No. In August 2024 the FDA approved Tecelra (afamitresgene autoleucel), which gives T cells an engineered T-cell receptor rather than a CAR, for MAGE-A4-positive synovial sarcoma.[14]

    Sources

    Each numbered claim is a statement we checked against the sources listed with it. Status shows how well established it is.

    1. [1]

      CAR T-cell therapy collects a patient's T cells, genetically engineers them to make chimeric antigen receptors, grows them to hundreds of millions and returns them as a single infusion, a process NCI puts at about 3 to 5 weeks. confirmedas of 2025-02-26

    2. [2]

      On 30 August 2017 the FDA approved the first CAR T-cell therapy, tisagenlecleucel (Kymriah), for children and young adults with B-cell acute lymphoblastic leukaemia; the overall remission rate within three months was 83%. confirmedas of 2017-08-30

    3. [3]

      In June 2026 China's NMPA approved CARsgen's satri-cel for claudin-18.2-positive, HER2-negative advanced gastric or gastro-oesophageal junction cancer, described as the first CAR T-cell therapy approved for a solid tumour. confirmedas of 2026-09-01

    4. [4]

      According to NCI, growing a patient's T cells in the lab takes 2 to 8 weeks, during which chemotherapy and sometimes radiation may be used to reduce the patient's other immune cells so the transferred T cells work better. confirmedas of 2024-08-05

    5. [5]

      In April 2024 the FDA required a boxed warning on six approved BCMA- or CD19-directed autologous CAR-T products for the risk of T-cell malignancies, and said patients should be monitored life-long for secondary cancers. confirmedas of 2024-04-18

    6. [6]

      On 8 November 2024 the FDA approved obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia. confirmedas of 2024-11-08

    7. [7]

      On 4 December 2025 the FDA approved lisocabtagene maraleucel (Breyanzi) as the first CAR T-cell therapy for marginal zone lymphoma; 95.5% of 66 treated patients responded. confirmedas of 2025-12-04

    8. [8]

      The main acute CAR-T toxicities are cytokine release syndrome, which can cause dangerously high fevers and steep drops in blood pressure, and neurotoxicity (ICANS), with symptoms such as confusion and impaired speech. confirmedas of 2025-02-26

    9. [9]

      On 26 June 2025 the FDA announced that the REMS programmes for approved BCMA- and CD19-directed autologous CAR-T therapies had been eliminated, saying a REMS was no longer necessary to ensure their benefits outweigh their risks. confirmedas of 2025-06-26

    10. [10]

      In June 2025 the FDA removed the REMS safety programmes for approved autologous CAR-T therapies, cutting the recommended stay near a treatment centre from four weeks to two and the driving restriction from eight weeks to two. confirmedas of 2025-10-02

    11. [11]

      NCI identifies three obstacles for CAR T cells in solid tumours: few suitable surface antigens, an immunosuppressive tumour environment, and molecular variation between and within tumours. confirmedas of 2025-02-26

    12. [12]

      In a randomised phase 2 trial of 156 patients with previously treated claudin-18.2-positive gastric or gastro-oesophageal junction cancer, the CAR-T therapy satri-cel extended median progression-free survival to 3.25 months versus 1.77 months with physician's choice (hazard ratio 0.37). confirmedas of 2025-06-01

    13. [13]

      CARsgen announced on 22 June 2026 that China's NMPA had approved satri-cel that day for Claudin18.2-positive, HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma after at least two prior lines of therapy. confirmedas of 2026-06-22

    14. [14]

      In August 2024 the FDA approved Tecelra (afamitresgene autoleucel) for adults with unresectable or metastatic synovial sarcoma expressing the MAGE-A4 antigen after prior chemotherapy, the first FDA-approved T-cell receptor (TCR) gene therapy. confirmedas of 2024-08-02

    15. [15]

      In the satri-cel trial, grade 3 or higher adverse events occurred in 99% of satri-cel patients versus 63% of controls, and cytokine release syndrome in 95% of treated patients. confirmedas of 2026-06-22

    16. [16]

      Researchers are developing off-the-shelf (allogeneic) CAR-T products made from healthy donors' T cells rather than each patient's own cells. confirmedas of 2025-02-26

    17. [17]

      ESO-T01 is a lentiviral vector given as a single intravenous infusion that generates anti-BCMA CAR-T cells inside the body, without leukapheresis, ex vivo manufacturing or lymphodepleting chemotherapy. confirmedas of 2026-04-01

    18. [18]

      In a phase 1 study of ESO-T01 in five patients with relapsed or refractory multiple myeloma, four responded, including three stringent complete remissions. confirmedas of 2026-04-01

    19. [19]

      Researchers describe ex vivo manufacturing of engineered T cells as lengthy and costly, limiting access, and current in vivo CAR-T methods as relying on either short-lived expression or random DNA integration. confirmedas of 2026-03-18

    20. [20]

      A 2026 Nature study used CRISPR-Cas9 delivered in vivo with a DNA template to insert a CAR gene at a T-cell-specific site, generating therapeutic levels of CAR-T cells in humanised mouse models; it was a preclinical study. confirmedas of 2026-03-18

    21. [21]

      On 5 March 2026 the FDA approved teclistamab, a BCMA x CD3 bispecific antibody, with daratumumab for relapsed or refractory myeloma after one prior line, based on the 587-patient MajesTEC-3 trial (progression-free survival hazard ratio 0.17). confirmedas of 2026-03-05

    22. [22]

      NCI describes two main types of T-cell transfer therapy: tumour-infiltrating lymphocyte (TIL) therapy and CAR T-cell therapy. confirmedas of 2026-10-10

    23. [23]

      T-cell engager labels such as tarlatamab's and teclistamab's carry boxed warnings for cytokine release syndrome and neurologic toxicity including ICANS. confirmedas of 2026-03-05

    Revision history (2)
    1. Page created.
    2. Refresh: dated the REMS removal from the FDA notice (26 June 2025), added CARsgen's approval announcement for satri-cel, Tecelra, lymphodepletion and in vivo gene-editing context.

    Created Oct 10, 2026. Last reviewed by an editor on Oct 10, 2026. Next scheduled review: Jan 10, 2027.

    Cite this page

    "CAR-T cell therapy." ContentLora, updated Oct 10, 2026. https://contentlora.com/wiki/car-t-cell-therapy

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    Keep exploring

    Connections
    In vivo CAR-T Next-generation approachTumour-infiltrating… Sister cell therapyBispecific antibodi… Shares targets and toxici…
    ☰ Contents